| Bid | 2.73 |
| Market Cap | 31.21M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.51 |
| PE Ratio (ttm) | -1.48 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.72 |
| Volume | 41,794 |
| Avg. Volume (20D) | 27,500 |
| Open | 3.53 |
| Previous Close | 3.64 |
| Day's Range | 3.53 - 3.87 |
| 52-Week Range | 2.19 - 4.20 |
| Beta | undefined |
About LSTA
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfun...
Analyst Forecast
According to 1 analyst ratings, the average rating for LSTA stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 303.44% from the latest price.
1 month ago · proactiveinvestors.com
Lisata Therapeutics advances certepetide with trial enrollment milestone and new diagnostic partnershipLisata Therapeutics Inc (NASDAQ:LSTA) shares were reacting positively this week after the company announced further developments for its lead investigational drug candidate, certepetide. The company ...
1 month ago · proactiveinvestors.com
Lisata Therapeutics completes patient enrollment for CENDIFOX trialLisata Therapeutics Inc (NASDAQ:LSTA) announced that it has completed patient enrollment in all three cohorts of its Phase 1b/2a CENDIFOX trial evaluating the safety and efficacy of Lisata's investiga...
1 month ago · proactiveinvestors.com
Lisata Therapeutics and Kuva Labs to collaborate on cancer imaging solutionLisata Therapeutics Inc (NASDAQ:LSTA) has announced a collaboration and license agreement with Kuva Labs, a wholly owned subsidiary of Mi2 Holdings. The clinical-stage pharmaceutical firm said the agr...
1 month ago · proactiveinvestors.com
Lisata Therapeutics named ‘Specialized BioTherapeutics Company of the Year' at 2024 BioTech Breakthrough AwardsLisata Therapeutics Inc (NASDAQ:LSTA) has been awarded the title of ‘Specialized BioTherapeutics Company of the Year' at the 2024 BioTech Breakthrough Awards. The company said it was recognized for it...
2 months ago · proactiveinvestors.com
Lisata Therapeutics CEO discusses pancreatic cancer trial progress and new collaborations - ICYMILisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to talk about the latest updates on its clinical trials and its third quarter financial performance. Mazzo highlighted advancemen...
2 months ago · seekingalpha.com
Lisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call TranscriptLisata Therapeutics, Inc. (NASDAQ:LSTA ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David Mazzo - President, C...
2 months ago · proactiveinvestors.com
Lisata Therapeutics advances clinical trials in Q3 ahead of 'data-rich' 2025Lisata Therapeutics Inc (NASDAQ:LSTA) reported significant advancements across its clinical portfolio in the third quarter, with multiple key data readouts projected over the next 18 months. Lisata's ...
2 months ago · proactiveinvestors.com
Lisata Therapeutics and Valo Therapeutics partner in preclinical study on cancer immunotherapyLisata Therapeutics Inc (NASDAQ:LSTA), the US-based clinical-stage pharmaceutical company, and Finnish immunotherapy developer Valo Therapeutics Oy have announced a preclinical research collaboration ...
2 months ago · proactiveinvestors.com
Lisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapy - ICYMILisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Dr Kristen Buck discussed with Proactive a promising collaboration between the company and the University of Cincinnati aimed at investigati...
2 months ago · proactiveinvestors.com
Lisata Therapeutics strikes research partnership to investigate new treatment for endometriosisLisata Therapeutics Inc (NASDAQ:LSTA) has entered a research agreement with the University of Cincinnati to study the use of its cyclic peptide, certepetide, combined with the VEGF inhibitor bevacizum...